be deduced that the NHR2 domain of ETO is essential in the leukemogenic capacity of the AML1-ETO fusion protein. The homo-oligomerization function imparted by the NHR2 domain appears to be the key mechanism for leukemogenesis in the pathogenesis of AML with t(8;21).
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, occurring in 32 per million children every year in the United States. 1 Racial differences in the incidence of ALL between blacks and whites have been well recognized. 2 Based on the Surveillance Epidemiology and End Results Program (SEER) data from 2000 to 2006, the ALL incidence in blacks was 16 per million person-years. 1 This was lower than the estimated incidence of 33 per million person-years in non-Hispanic whites, a finding similar to that reported by McNeil. 2 ALL is also a heterogeneous disease including multiple subtypes. 3 The distribution of ALL subtypes also differs between blacks and whites. 4 A higher percentage of blacks with ALL have T-cell ALL or B-lineage ALL with the TCF3-PBX1 fusion, where as a higher percentage of whites have B-lineage hyperdiploid ALL. 4 In about 70% of cases, SEER distinguished T-cell ALL from B-lineage ALL, but there was no information on ploidy or chromosomal translocations. Therefore, we estimated the subtype-specific incidence in blacks and whites based on the overall incidence of ALL using SEER data 1 and the distribution of ALL subtypes that we observed in 560 patients with newly diagnosed ALL enrolled on St Jude trials, including 112 black patients and 448 non-Hispanic white patients ( Figure 1 ). We focused on four major non-overlapping ALL subtypes with sufficient numbers of patients, including T-cell ALL, B-lineage hyperdiploid ALL with X50 chromosomes, B-lineage ALL bearing the t(12;21)/ETV6-RUNX1 fusion, and B-lineage ALL without defined genetic or chromosomal abnormalities (that is, without hyperdiploidy, hypodiploidy, TCF3-PBX1, BCR-ABL, MLL/AF4 or ETV6-RUNX1). We estimated that the incidence of T-cell ALL does not differ between blacks and whites (3.7 vs 4.8 per million person-years, P ¼ 0.17), and that the incidence of B-lineage ALL was lower in blacks (9.3 per million person-years) than in whites (25.2 per million person-years, Po1 Â 10 À6 ). According to those SEER data that were evaluable, the incidence of T-cell ALL was also similar in blacks and whites (both at 3 per million person-years), whereas the incidence of B-lineage ALL was about 8 per million person-years in blacks vs 21 per million person-years in whites, comparable with what we had estimated. In addition, our data showed that the incidence of B-hyperdiploid ALL differed significantly between whites and blacks (9.8 vs 2.1 per million person-years, relative risk (RR) ¼ 4.6 for whites compared with blacks), as did B-lineage ALL without defined genetic or chromosomal abnormalities (RR ¼ 2.6) and B-lineage ALL with the t(12;21)/ETV6-RUNX1 fusion (RR ¼ 1.6).
We hypothesized that the racial differences in ALL incidence could partly be attributed to differences in allele frequencies between populations of African and European ancestries at disease-associating loci. We have recently identified that germline diversity in the ARID5B gene (SNP rs10821936) was significantly associated with childhood ALL risk in non-Hispanic whites based on a genome-wide association analysis. 5 An ARID5B SNP in high linkage disequilibrium with rs10821936 was also associated with ALL risk in an independent study. 6 The high-risk genotypes at rs10821936 particularly increased the risk of developing the B-hyperdiploid ALL subtype. Here we performed a case-control analysis to investigate whether genotypes at rs10821936 were also associated with the risk of developing childhood ALL in blacks.
Patients included 93 black children with newly diagnosed ALL enrolled on St Jude Trials Total XIIIB and Total XV between 1994 and 2007. Controls included 112 unrelated subjects from the International HapMap Project (www.hapmap.org), including 52 unrelated subjects of African ancestry in Southwest USA (ASW) and 60 Yoruban (YRI) samples. Patient genotypes were assessed by Affymetrix 500K or SNP6.0 Mapping array and confirmed by an independent genotyping method as described. 5 Genotypes of controls were downloaded from Hapmap version 29. Logistic regression and Fisher's exact test were used to compare the differences in allele and genotype frequencies at the ARID5B SNP rs10821936 between patients with ALL and controls. The frequency of the C risk allele at rs10821936 was significantly higher in black children with ALL (minor allele frequency ¼ 0.33) than in controls of African ancestry (0.163 in ASW and 0.20 in YRI, odds ratio (OR) ¼ 2.08; 95% confidence interval (CI) 1.32-3.27, P ¼ 0.0015, Table 1 ). Black patients carrying one or two copies of the C allele at rs10821936 had a higher risk of developing B-hyperdiploid ALL compared with controls (OR ¼ 6.62; 95% CI 2.0-21.9; P ¼ 0.0001), similar to our previous findings in whites. The ORs relating this ARID5B genotype to the other subtypes of ALL were moderate, ranging from 2.01 in patients with t(12;21)/ETV6-RUNX1 fusion to 2.80 in those with T-cell ALL. The ORs relating ARID5B SNPs to subtype-specific ALL risk were similar in magnitude between blacks and whites ( Table 2) .
It is notable that the frequency of the C risk allele was lower in the control populations of African ancestry (0.163 in ASW, 0.20 in YRI) than in populations of European Ancestry (0.33). 5 The question then naturally arises as to whether this allele frequency difference in the general population might contribute to racial differences in the incidence of ALL. To this end, we calculated the absolute risk of developing ALL in whites with different rs10821936 genotypes, based on the average subtype-specific incidence and the RR between genotypes. Because ALL is a rare disease, the afore-estimated ORs can be considered to be essentially equivalent to the RRs. If the frequency of the C risk allele in whites were 0.18 (the same frequency as in blacks), instead of the observed 0.33, we would expect only 7 per million person-years to develop B-hyperdiploid ALL, compared with the observed 9.8 per million person-years observed in whites in the United States. Therefore, 2.8 per million personyears of B-hyperdiploid cases among whites could be explained by the greater frequency of the high-risk rs10821936 genotypes in whites compared with blacks (hatched area in Figure 1 ). Combining the four major ALL subtypes, a total of 5.2 per million person-years (30% of the observed racial difference in ALL incidence) could be attributed to the higher frequency of the risk allele at rs10821936 in whites compared with blacks.
Our data show that the inherited variation at rs10821936 in the ARID5B gene is associated with the risk of developing childhood ALL in blacks, as we previously described in non-Hispanic American whites. 5 This further indicates the Figure 1 The subtype-specific US incidence of ALL in blacks and non-Hispanic whites. The hatched areas indicate cases in whites that can be attributed to a higher frequency of the risk allele at rs10821936 in whites compared with blacks. Numbers in parentheses are the estimated incidence of ALL in whites if the frequency of high-risk genotypes at rs10821936 were the same in whites as in blacks. B-other includes B-lineage ALL without defined genetic or chromosomal abnormalities. Letters to the Editor importance of the ARID5B gene region in the etiology of childhood ALL, and it is remarkable that the identical SNP is penetrant for ALL risk in both racial groups. It is noteworthy that this single locus explains approximately 30% of the racial difference in ALL incidence between blacks and whites. Nevertheless, even after accounting for the racial differences in frequency of the risk allele at rs10821936, there remains a lower incidence of B-lineage ALL in blacks. These unexplained racial differences could be due to racial differences in allele frequencies at additional inherited loci, in environmental exposure to leukemogens, or in immune function. 7 In addition, B-lineage ALL without known cytogenetic abnormalities could include a heterogeneous group of cryptic genomic variations such as chromosomal gains or losses. 8 It is possible that germline polymorphisms are associated with subgroups of ALL cases with cryptic gains or losses. Future systematic cataloging of race-specific lesions in ALL patients should shed new light on the etiology of this disease.
Imatinib (STI-571, Gleevec; Novartis, Basel, Switzerland) is an adenosine-5 0 -triphosphate (ATP)-competitive tyrosine kinase inhibitor that is highly effective in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. This compound potently inhibits Bcr-Abl, the fusion protein that causes the onset of Philadelphia chromosome-positive chronic myeloid leukemia, and it also inhibits the receptor tyrosine Abbreviation: ALL, acute lymphoblastic leukemia. a Odds ratio is estimated using logistic regression comparing allele frequencies or genotype frequencies between ALL cases and controls. Controls for whites included individuals as previously described; 5 controls for blacks included 112 subjects as described in the text.
